Page 103 - Demo

Plasma microRNAs in oesophageal and gastric cancer101520. Kogo, R.; Mimori, K.; Tanaka, F.; Komune, S.; Mori, M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 2011, 17, 4277-4284, doi:10.1158/1078-0432.CCR-10-2866.21. Fu, W.; Pang, L.; Chen, Y.; Yang, L.; Zhu, J.; Wei, Y. The microRNAs as prognostic biomarkers for survival in esophageal cancer: a meta-analysis. ScientificWorldJournal 2014, 2014, 523979, doi:10.1155/2014/523979.22. Wu, C.; Li, M.; Hu, C.; Duan, H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep 2014, 41, 1257-1266, doi:10.1007/s11033-013-2970-z.23. Yu, H.; Duan, B.; Jiang, L.; Lin, M.; Sheng, H.; Huang, J.; Gao, H. Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res 2013, 6, 71-77.24. Tanaka, K.; Miyata, H.; Yamasaki, M.; Sugimura, K.; Takahashi, T.; Kurokawa, Y.; Nakajima, K.; Takiguchi, S.; Mori, M.; Doki, Y. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013, 20 Suppl 3, S607-615, doi:10.1245/s10434-013-3093-4.25. Wen, S.W.; Zhang, Y.F.; Li, Y.; Liu, Z.X.; Lv, H.L.; Li, Z.H.; Xu, Y.Z.; Zhu, Y.G.; Tian, Z.Q. Association of miR-21 with esophageal cancer prognosis: a meta-analysis. Genet Mol Res 2015, 14, 6578-6582, doi:10.4238/2015.June.12.12.26. Giovannetti, E.; Funel, N.; Peters, G.J.; Del Chiaro, M.; Erozenci, L.A.; Vasile, E.; Leon, L.G.; Pollina, L.E.; Groen, A.; Falcone, A., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010, 70, 4528-4538, doi:10.1158/0008-5472.CAN-09-4467.27. Zhang, B.X.; Yu, T.; Yu, Z.; Yang, X.G. MicroRNA-148a regulates the MAPK/ERK signaling pathway and suppresses the development of esophagus squamous cell carcinoma via targeting MAP3K9. Eur Rev Med Pharmacol Sci 2019, 23, 6497-6504, doi:10.26355/eurrev_201908_18533.28. van Zweeden, A.A.; van Groeningen, C.J.; Honeywell, R.J.; Giovannetti, E.; Ruijter, R.; Smorenburg, C.H.; Giaccone, G.; Verheul, H.M.W.; Peters, G.J.; van der Vliet, H.J. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. Cancer Chemother Pharmacol 2018, 82, 39-48, doi:10.1007/s00280-018-3588-6.29. Freedman, J.E.; Gerstein, M.; Mick, E.; Rozowsky, J.; Levy, D.; Kitchen, R.; Das, S.; Shah, R.; Danielson, K.; Beaulieu, L., et al. Diverse human extracellular RNAs are widely detected in human plasma. Nat Commun 2016, 7, 11106, doi:10.1038/ncomms11106.30. Luo, H.S.; Wu, D.H. Identification of miR-375 as a potential prognostic biomarker for esophageal squamous cell cancer: A bioinformatics analysis based on TCGA and meta-analysis. Pathol Res Pract 2019, 215, 512-518, doi:10.1016/j.prp.2019.01.009.31. Huang, M.; Wu, L.; Qin, Y.; Li, Z.; Luo, S.; Qin, H.; Yang, Y.; Chen, J. Anti-proliferative role and prognostic implication of miR-141 in gastric cancer. Am J Transl Res 2016, 8, 3549-3557.32. Wang, X.X.; Ge, S.J.; Wang, X.L.; Jiang, L.X.; Sheng, M.F.; Ma, J.J. miR-218 tissue expression level is associated with aggressive progression of gastric cancer. Genet Mol Res 2016, 15, doi:10.4238/gmr.15027521.33. Poel, D.; Buffart, T.E.; Oosterling-Jansen, J.; Verheul, H.M.; Voortman, J. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Exp Mol Med 2018, 50, e454, doi:10.1038/emm.2017.288.34. Bai, X.H.; Fischer, S.; Keshavjee, S.; Liu, M.Y. Heparin interference with reverse transcriptase polymerase chain reaction of RNA extracted from lungs after ischemia-reperfusion. Transplant Int 2000, 13, 146-150, doi:DOI 10.1111/j.1432-2277.2000.tb01055.x.35. Johnson, M.L.; Navanukraw, C.; Grazul-Bilska, A.T.; Reynolds, L.P.; Redmer, D.A. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques 2003, 35, 1140-1142, 1144, doi:10.2144/03356bm03.36. Pritchard, C.C.; Kroh, E.; Wood, B.; Arroyo, J.D.; Dougherty, K.J.; Miyaji, M.M.; Tait, J.F.; Tewari, M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012, 5, 492-497, doi:10.1158/1940-6207.CAPR-11-0370.37. Lippi, G.; Cadamuro, J.; von Meyer, A.; Simundic, A.M.; European Federation of Clinical, C.; Laboratory Medicine Working Group for Preanalytical, P. Practical recommendations for managing hemolyzed samples in clinical chemistry testing. Clin Chem Lab Med 2018, 56, 718-727, doi:10.1515/cclm-2017-1104.